FORA Capital LLC Invests $1.41 Million in Hims & Hers Health, Inc. (NYSE:HIMS)

FORA Capital LLC purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 76,586 shares of the company's stock, valued at approximately $1,411,000.

Other institutional investors also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. purchased a new position in Hims & Hers Health during the third quarter valued at $604,000. Carnegie Investment Counsel bought a new position in shares of Hims & Hers Health in the 3rd quarter worth about $5,531,000. Royce & Associates LP lifted its position in Hims & Hers Health by 17.0% during the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company's stock valued at $6,281,000 after acquiring an additional 49,500 shares during the period. Versor Investments LP bought a new stake in Hims & Hers Health during the third quarter worth about $634,000. Finally, International Assets Investment Management LLC purchased a new stake in Hims & Hers Health in the third quarter worth about $6,790,000. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Trading Down 1.1 %

NYSE:HIMS traded down $0.34 during trading hours on Thursday, reaching $30.34. The company had a trading volume of 24,738,795 shares, compared to its average volume of 9,806,751. The firm has a market cap of $6.63 billion, a price-to-earnings ratio of 68.98 and a beta of 1.06. The firm's 50 day moving average price is $21.14 and its 200-day moving average price is $19.57. Hims & Hers Health, Inc. has a 52 week low of $8.09 and a 52 week high of $35.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analysts' expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health's revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.04) earnings per share. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HIMS. TD Cowen reissued a "buy" rating and issued a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research note on Wednesday, November 6th. Needham & Company LLC initiated coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a "buy" rating and a $24.00 target price on the stock. Canaccord Genuity Group lifted their price target on Hims & Hers Health from $24.00 to $28.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Finally, Bank of America cut shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and dropped their price target for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Hims & Hers Health currently has an average rating of "Hold" and a consensus price target of $20.71.

Insider Activity

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,609 shares of the business's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.60, for a total transaction of $169,491.40. Following the completion of the sale, the chief financial officer now owns 181,469 shares of the company's stock, valued at approximately $2,649,447.40. The trade was a 6.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Soleil Boughton sold 2,345 shares of the firm's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the transaction, the insider now directly owns 159,796 shares in the company, valued at $2,341,011.40. This trade represents a 1.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,153,519 shares of company stock valued at $24,486,721 in the last quarter. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.